Patent intelligence · US
US 11034739
Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases
Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases
Patent details — US 11034739
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 15, 2021
- Expiration
- Jun 10, 2041
- Applicant
- The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada
- Claims
- 15
- CPC classes
- A61K, A61K38/00, A61P, A61P25/28
Quick answer
US 11034739 (Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases) is held by The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada. Status: granted. Granted Jun 15, 2021. Expires Jun 10, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K38/00, A61P, A61P25/28
More from The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11034739?
US 11034739 (Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases) is held by The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada. Status: granted. Granted Jun 15, 2021. Expires Jun 10, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11034739?
The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11034739 expire?
Our index shows an expiration date of Jun 10, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.